Tobias Banaschewski
Medical Director of the Clinic for Child and Adolescent Psychiatry and Psychotherapy and Deputy Director of the Central Institute of Mental Health.
The Central Institute of Mental Health (Zentralinstitut für Seelische Gesundheit) in Mannheim, Germany, is a leading psychiatric research institution affiliated with Heidelberg University. It specializes in research, treatment, and education related to mental health disorders, neuroscience, and psychosocial factors influencing mental well-being. The institute plays a crucial role in advancing psychiatric knowledge and developing innovative therapies through interdisciplinary collaboration and state-of-the-art facilities.

Medical Director of the Clinic for Child and Adolescent Psychiatry and Psychotherapy and Deputy Director of the Central Institute of Mental Health.
Gabriele Ende is a researcher associated with the Central Institute of Mental Health (ZI) in Mannheim, Germany. Her work primarily focuses on neuroimaging and the application of magnetic resonance spectroscopy (MRS) in psychiatric and neurological disorders. Ende’s research aims to deepen the understanding of brain chemistry and its alterations in various mental health conditions.
Nathalie Holz is leader of the research group Developmental neuroscience in psychiatry at the ZI Mannheim.
Andreas Meyer-Lindenberg is a distinguished psychiatrist and neuroscientist based in Germany, renowned for his groundbreaking research on the neurobiological underpinnings of psychiatric disorders. He serves as the Director of the Central Institute of Mental Health (ZI) in Mannheim and is a professor at the University of Heidelberg. Meyer-Lindenberg’s work focuses on understanding how genetic and environmental factors influence brain function and contribute to mental illnesses such as schizophrenia and depression. His contributions have significantly advanced the field of psychiatric neuroscience, providing deeper insights into the mechanisms of mental health disorders and informing the development of more effective treatments.
This is a distributed project, with representatives at all main TRR379 sites.